InspireMDNSPR
NSPR
About: InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
Employees: 80
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
17% more funds holding
Funds holding: 24 [Q2] → 28 (+4) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
5% less capital invested
Capital invested by funds: $35.1M [Q2] → $33.2M (-$1.92M) [Q3]
8.12% less ownership
Funds ownership: 56.36% [Q2] → 48.24% (-8.12%) [Q3]
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$5
67%
upside
Avg. target
$5
67%
upside
High target
$5
67%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Lake Street Frank Takkinen 58% 1-year accuracy 11 / 19 met price target | 67%upside $5 | Buy Initiated | 11 Dec 2024 |
Financial journalist opinion
Based on 3 articles about NSPR published over the past 30 days
Positive
Zacks Investment Research
1 week ago
NSPR Stock May Gain as First Patient Enrolls in CGUARDIANS II Study
InspireMD announces the first patient enrolment in the CGUARDIANS II clinical trial.
Neutral
GlobeNewsWire
1 week ago
InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)
Study represents a significant step forward in Company's mission to serve the broadest set of physician and patient needs with best-in-class CAS and TCAR solutions Study represents a significant step forward in Company's mission to serve the broadest set of physician and patient needs with best-in-class CAS and TCAR solutions
Neutral
GlobeNewsWire
3 weeks ago
InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors
MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE: ABT) in April 2023.
Neutral
Seeking Alpha
1 month ago
InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript
InspireMD, Inc. (NASDAQ:NSPR ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Chuck Padala - IR, Life Advisors Marvin Slosman - CEO Craig Shore - CFO Shane Gleason - CCO Conference Call Participants Adam Maeder - Piper Sandler Operator Good day, everyone, and welcome to the InspireMD Third Quarter 2024 Earnings Call. Currently, all participants are in a listen-only mod e.
Negative
Zacks Investment Research
1 month ago
InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.15 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, Nov. 08, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to five new non-executive employees in the aggregate amount of 197,167 shares of restricted stock outside of InspireMD's 2021 Equity Compensation Plan, with a grant date as of October 24, 2024, as an inducement material to the employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
2 months ago
InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System
MIAMI, Oct. 15, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the establishment of its global headquarters in Miami, Florida. The new facility will ideally position the Company to support the anticipated U.S. launch and commercialization of the CGuard Prime carotid stent system in the first half of 2025, if approved.
Positive
Zacks Investment Research
2 months ago
InspireMD Gains FDA Premarket Approval for CGuard Prime Carotid Stent
NSPR gains premarket approval for its CGuard Prime carotid stent system for use in United States for treating carotid artery stenosis.
Neutral
GlobeNewsWire
2 months ago
InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System
MIAMI, Oct. 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational Device Exemption (IDE) Application to initiate the CGUARDIANS II pivotal study of its CGuard Prime 80cm Carotid Stent System during transcarotid revascularization (TCAR) procedures.
Neutral
Zacks Investment Research
3 months ago
NSPR Stock Declines Despite PMA Application Submission for CGuard
InspireMD announces the submission of the PMA application to the FDA for marketing approval of the CGuard Prime EPS.
Charts implemented using Lightweight Charts™